Davion Healthcare (DAVI) Registration filing summary

Company overview and business model

• Develops non-diagnostic, non-invasive home tests for early warning of potential health anomalies; positive or concerning results require clinical follow-up.

• Four completed products: BreastCheck, FootFlow, Testic and ThermaDerm; BreastCheck is planned for U.S. launch in H1 2026, with FootFlow anticipated six months later.

• Liquid-crystal film maps skin-temperature differences; smartphone images are analyzed with AI to standardize results. Products are positioned as OTC adjuncts, not substitutes for diagnosis.

• Commercial model relies on third-party R&D, outsourced manufacturing and design, and licensing for manufacturing, sales and international distribution.

• NeuRX Health has exclusive worldwide BreastCheck manufacturing and distribution rights for an initial 10-year term, with an option to renew for another 10 years.

Financial performance and metrics

• No revenue through the filing date; operating loss was €1.32M in FY2024 versus €5.31M in FY2023; basic and diluted loss per share was €0.06 and €0.35, respectively.

• At Dec. 31, 2024, cash was €11, intangible assets €65M, total equity €64.97M and liabilities €39,756; 2024 and 2023 statements were restated.

• FY2023 R&D expense was €3.02M; R&D spending fell substantially in FY2024 after the four products were market-ready.

• Management cites CEO financial support and anticipated NeuRX inflows as sufficient for obligations over the next 12 months; the support letter is not legally binding.

• FY2024 and FY2023 financial statements are IFRS-based and audited by PCAOB-registered WithumSmith + Brown; audits identified material weaknesses that contributed to restatements.

Use of proceeds and capital allocation

• No shares are being sold by the issuer and no proceeds will be received from registered-shareholder resales; any later capital raise would require a separate filing or exemption.

• Estimated registration and listing expenses total $871,900, funded through non-interest-bearing, unsecured advances from Malbrite Ltd, controlled by CEO Jack Kaye, repayable only after a future capital raise.

• Available funds and future earnings are intended to be retained for business operations and expansion; no cash dividends are planned for the foreseeable future.